Akebia Therapeutics (AKBA) Shares Outstanding (Weighted Average) (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Shares Outstanding (Weighted Average) data on file, last reported at $267.0 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $267.0 million, up 13.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $267.0 million (up 13.4% YoY), and the FY2025 annual result was $257.2 million, up 21.91% from the prior year.
• Shares Outstanding (Weighted Average) improved to $267.0 million in Q1 2026 per AKBA's latest filing, from $257.2 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $267.0 million in Q1 2026 and troughed at $179.6 million in Q1 2022.
• A 5-year average of $211.4 million and a median of $205.0 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2023 and 2025: Shares Outstanding (Weighted Average) rose 2.34% in 2023, then gained 27.09% in 2025.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $182.8 million in 2022, then climbed by 2.56% to $187.5 million in 2023, then rose by 12.53% to $210.9 million in 2024, then climbed by 21.91% to $257.2 million in 2025, then grew by 3.85% to $267.0 million in 2026.
• Business Quant data shows AKBA's Shares Outstanding (Weighted Average) at $267.0 million in Q1 2026, $257.2 million in Q4 2025, and $264.8 million in Q3 2025.